Selinexor
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 96 patients (estimated)
- Sponsors
- John Theurer Cancer Center at Hackensack University Medical Center
- Collaborators
- Karyopharm Therapeutics
- Tags
- Selective Inhibiton of Nuclear Export (SINE)
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1114
- NCT Identifier
- NCT04661137
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.